Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding.
Danaher Corporation and MDS, Inc., In the Matter of
The Commission challenged Danaher’s proposed acquisition of MDS Analytical Technologies, requiring that MDS divest its assets related to its laser microdissection business. The proposed settlement is designed to preserve competition in the North American market for laser microdissection devices – a key tool for scientific research.
Service Corporation International, In the Matter of
The Commission challenged Service Corporation International's (SCI) proposed acquisition of local rival Palm Mortuary, Inc. At the time of the acquisition, SCI, the nation’s largest cemetery operator, was the third-largest provider of cemetery services in Las Vegas, Nevada, and after the acquisition of Palm, would have controlled 76 percent of the market for funeral services, which includes burial plots, opening and closing of graves, memorials, burial vaults, mausoleum spaces, and cemetery maintenance. The Commission's order required SCI to sell its cemetery and funeral home in Las Vegas to complete the acquisition of Palm.
Watson Pharmaceuticals, Inc., a corporation, and Robin Hood Holdings Limited, a limited liability company, In the Matter of
The Commission charged that Watson Pharmaceuticals, Inc.’s acquisition of Robin Hood Holdings Limited, owner of Arrow Pharmaceuticals, would have harmed consumers by eliminating future competition for important generic drugs used to treat Parkinson’s disease (cabergoline) and the side effects of chemotherapy (dronabinol). The Commission’s order requires the firms to sell assets related to the two drugs to FTC-approved buyers and to ensure the acquirers have the means to compete effectively in the future.
There is a related federal proceeding and two related administrative proceedings:
CSE, Inc., also d/b/a MAD MOD, and Chris Saetveit and Cyndi Saetveit, individually and as owners of the corporation, In the Matter of
Statement of Chairman Leibowitz and Commissioner Rosch, In the Matter of Intel Corporation
Concurring and Dissenting Statement of Commissioner Rosch, In the Matter of Intel Corporation
K+S Aktiengesellschaft and International Salt Company LLC, In the Matter of
The FTC announced a consent order that will maintain competition in the market for bulk de-icing road salt in Maine and Connecticut that otherwise would have been lost as a result of K+S Aktiengesellschaft’s (K+S) $1.68 billion proposed acquisition of Morton International, Inc. To protect state and local governments from higher prices, the order requires K+S’s U.S. subsidiary, International Salt Company LLC (ISCO), to sell its bulk de-icing salt assets in Maine to Eastern Salt Company, Inc., and to sell a similar set of assets in Connecticut to Granite State Minerals, Inc.
Statement of FTC Chairman Jon Leibowitz Regarding the Announcement that Arthur D. Levinson Has Resigned from Google's Board
Successful Credit Service Corporation, et al., FTC
Constellation Brands, Inc., a corporation, In the Matter of
National Prize Information Group Corp. et al.
Thoratec Corporation, and HeartWare International, Inc., In the Matter of
The Commission authorized a preliminary injunction to block Thoratec Corporation’s proposed $282 million acquisition of rival medical device maker HeartWare International, Inc., charging that the transaction would substantially reduce competition in the U.S. market for left ventricular devices (LVADs), a life-sustaining treatment for patients with advanced heart failure. The FTC’s administrative complaint alleges that Thoratec seeks to maintain its monopoly by acquiring HeartWare, thus eliminating the only significant threat to Thoratec’s continued dominance of the LVAD market. In August of 2009, the parties announced they would not to proceed with the proposed acquisition, and the Commission dismissed the Administrative Complaint without filing an motion for preliminary injunction in federal court.